Neulastim

Neulastim

pegfilgrastim

Manufacturer:

Amgen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Pegfilgrastim
Indications/Uses
Reduction in the duration of neutropenia & incidence of febrile neutropenia in patients treated w/ cytotoxic chemotherapy for malignancy (w/ exception of chronic myeloid leukemia & myelodysplastic syndromes).
Dosage/Direction for Use
Adult ≥18 yr 1 SC inj for each chemotherapy cycle 24 hr following cytotoxic chemotherapy.
Contraindications
Hypersensitivity to pegfilgrastim, filgrastim, E coli-derived proteins.
Special Precautions
Hypersensitivity. Long-term effects in acute myeloid leukaemia (AML). Not to be used in myelodysplastic syndrome, chronic myelogenous leukemia & secondary AML. De novo AML patients <55 yr; recent history of pulmonary infiltrates or pneumonia; glumerulonephritis; sickle cell trait or disease. Immunogenicity; aortitis. Monitor for preliminary signs of acute resp distress syndrome; urinalysis. Closely monitor patients who develop capillary leak syndrome & spleen size. Regularly monitor platelet count & hematocrit. Regularly perform WBC count. May cause allergic reactions due to latex. Mobilisation of blood progenitor cells in patients or healthy donors. High-dose use. Fructose intolerance. Women of childbearing potential should use effective contraception. Not recommended during pregnancy. Lactation. Childn.
Adverse Reactions
Headache; nausea; bone pain. Thrombocytopenia, leukocytosis; musculoskeletal pain; inj site & non-cardiac chest pain.
Drug Interactions
Myelosuppressive cytotoxic chemotherapeutic agents.
MIMS Class
Haematopoietic Agents / Supportive Care Therapy
ATC Classification
L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
Presentation/Packing
Form
Neulastim soln for inj 6 mg
Packing/Price
0.6 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in